Stock Price, News, Quote and Profile of ASTRIA THERAPEUTICS INC(NASDAQ:ATXS) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (12/18/2024, 10:38:46 AM)

9.705

+0.15 (+1.62%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month1.27%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap547.65M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

Short Float %

Short Ratio

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2015-06-25. The firm's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The firm owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Company Info

ASTRIA THERAPEUTICS INC

22 Boston Wharf Road, 10Th Floor

Boston MASSACHUSETTS

P: 16173491971

CEO: Jill C. Milne

Employees: 59

Website: https://astriatx.com/

ATXS News

6 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.